Meredith Cook Sells 250 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of ANI Pharmaceuticals stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $56.82, for a total value of $14,205.00. Following the completion of the transaction, the vice president now owns 56,738 shares in the company, valued at $3,223,853.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Meredith Cook also recently made the following trade(s):

• On Tuesday, August 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $59.62, for a total value of $14,905.00.
• On Friday, July 12th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $64.91, for a total value of $16,227.50.

ANI Pharmaceuticals Trading Up 6.9 %

Shares of ANI Pharmaceuticals stock opened at $60.06 on Wednesday. ANI Pharmaceuticals, Inc. has a 52-week low of $48.20 and a 52-week high of $70.81. The firm has a market capitalization of $1.26 billion, a PE ratio of 37.54 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. The company’s fifty day moving average price is $61.27 and its two-hundred day moving average price is $63.85.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. The business had revenue of $138.00 million for the quarter, compared to analysts’ expectations of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The firm’s revenue for the quarter was up 18.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.06 earnings per share. On average, analysts expect that ANI Pharmaceuticals, Inc. will post 3.5 EPS for the current year.

Wall Street Analysts Forecast Growth

ANIP has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday. Truist Financial reiterated a “hold” rating and issued a $60.00 target price (down previously from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. Finally, StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $77.75.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Innealta Capital LLC bought a new stake in ANI Pharmaceuticals in the second quarter valued at $65,000. Ridgewood Investments LLC bought a new stake in shares of ANI Pharmaceuticals in the 2nd quarter worth about $85,000. SG Americas Securities LLC bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth about $106,000. ADAR1 Capital Management LLC bought a new position in ANI Pharmaceuticals during the 4th quarter valued at about $132,000. Finally, Clear Street Markets LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at about $140,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.